| Name | Title | Contact Details |
|---|
Sciex helps to improve the world we live in by enabling scientists and laboratory analysts to find answers to the complex analytical challenges they face. The company`s global leadership and world-class service and support in the capillary electrophoresis and liquid chromatography-mass spectrometry industry have made it a trusted partner to thousands of the scientists and lab analysts worldwide who are focused on basic research, drug discovery and development, food and environmental testing, forensics and clinical research. With over 40 years of proven innovation, SCIEX excels by listening to and understanding the ever-evolving needs of its customers to develop reliable, sensitive and intuitive solutions that continue to redefine what is achievable in routine and complex analysis.
Caladrius is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of cell therapies designed to reverse disease and/or promote the regeneration of damaged tissue. The Company is developing first-in-class therapeutics based on the characteristics of naturally occurring CD34+ cells and their ability to stimulate the growth of new microvasculature. The Company`s platform technology leverages these cells to enable the body`s natural repair mechanisms using formulations unique to each medical indication.
Aura Biosciences is a clinical-stage biotechnology company developing virus-like drug conjugates (VDC), a novel class of therapies, for the treatment of multiple oncology indications. At Aura, our mission is to deliver meaningful therapeutic benefit to a range of cancer indications with high unmet need in which we believe we can establish a new standard of care. We are driven by our passion and commitment to science and the patients battling cancer who are relying on us to pioneer these new therapies. We are focusing the initial development of our VDC technology platform to treat tumors of high unmet need in ocular and urologic oncology. Belzupacap sarotalocan (bel-sar), our first VDC candidate, is being developed for the first-line treatment of early-stage choroidal melanoma, a rare disease with no drugs approved. Beyond early-stage choroidal melanoma, we are developing bel-sar in additional ocular oncology indications, including choroidal metastasis. Leveraging our VDCs` broad tumor targeting capabilities, we have also initiated a clinical program in non-muscle invasive bladder cancer, or NMIBC, our first non-ocular solid tumor indication.
NextBio is a Santa Clara, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Relypsa is a biopharmaceutical company leading the discovery, development and commercialization of polymer-based medicines to treat conditions that are often overlooked and undertreated, but that can have a serious impact on patient lives or even be life-threatening. Relypsa was founded in October 2007 and is headquartered in Redwood City, Calif. In 2015, we received FDA approval for our first medicine, which was developed based on our polymer technology platform for the treatment of hyperkalemia. In September 2016, Relypsa became a Vifor Pharma company. Today, we have more than 400 employees united by a passion for improving people’s lives.